Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 73 for your search:
Cancer Type/Condition:
Leukemia, chronic lymphocytic (CLL)
Stage/Subtype:
stage II chronic lymphocytic leukemia
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
POI-02818
, NIP-02-005, NCT00131313
2.
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
19 to 70
Sponsor:
Other
Protocol IDs:
F080429003
, UAB-0775, NCT00714259
3.
Ofatumumab + Chlorambucil vs. Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
OMB110911
, EudraCT 2008-004932-19, NCT00748189
4.
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CC-5013-CLL-002
, NCT00774345
5.
Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
110913
, NCT00824265
6.
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
65 and ovr
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CC-5013-CLL-008
, Eudract #: 2008-003079-32, NCT00910910
7.
Phase I/II Study of Fludarabine and Thalidomide as Front-Line Therapy in Patients With Newly Diagnosed B-Cell Chronic Lymphocytic Leukemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
RPCI-RPC-0112
, CELGENE-RPCI-RPC-0112, NCT00096018
8.
Phase I/II Study of Green Tea Extract (Polyphenon E) in Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-MC0419
, 7303, NCI-7303, NCT00262743, CLLT-MAYO-MC0419
9.
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2006-1026
, NCT00472849
10.
Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
BCM-H-19386
, BCM-FAB, H 19386, NCT00625144
11.
Phase I/II Study of CD40-Ligand Expressing and Interleukin-2 Gene Modified Autologous Tumor Cells in Patients With B-Cell Chronic Lymphocytic Leukemia
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
BCM-H-19747
, H 19747, BCM-PRIMAL, NCT00602121
12.
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
0 to 55
Sponsor:
Other
Protocol IDs:
8717
, NCT00673114
13.
Study of AMD3100 and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 80
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
MOZ00207
, NCT00694590
14.
Phase I/II Study of Vorinostat, Cladribine, and Rituximab in Patients With Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Relapsed B-Cell Non-Hodgkin Lymphoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 85
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
OHSU-4180
, 4180, OHSU-HEM-08002-L, MERCK-OHSU-4180, NCT00764517
15.
Phase I/II Study of T-Cell-Reduced Unrelated Donor Peripheral Blood Stem Cell Transplantation After Reduced-Intensity Conditioning Comprising Pentostatin and Low-Dose Total-Body Irradiation in Patients With Hematological Malignancies
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
19 to 75
Sponsor:
NCI
Protocol IDs:
UNMC-16407
, 164-07, NCT00816413
16.
A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
SCLL084993
, NCT00829647
17.
Phase I/II Study of Induction Therapy Comprising Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab Followed by Maintenance Therapy Comprising Vorinostat and Rituximab in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
PSOC-2401
, PSOC-2401, IR-6956, MERCK-PSOC-2401, NCT00918723
18.
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
14341B
, NCT00943592
19.
A Study of Dasatinib + Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
UCSD-080422
, NCT00949988
20.
Phase II Study of Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Disease or Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
8 to 80
Sponsor:
NHLBI
Protocol IDs:
NHLBI-99-H-0050
, NCT00003838
21.
Phase II Study of LMB-2 Immunotoxin in Patients With CD25-Positive Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-04-C-0121
, NCI-6074, 6074, NCT00080821
22.
Phase II Study of Rituximab, High-Dose Cyclophosphamide, and Pegfilgrastim in Patients With B-Cell Leukemia or Low-Grade or Mantle Cell Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
NCI
Protocol IDs:
JHOC-J0260
, J0260, JHOC-03022409, NCT00278161
23.
Phase II Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
LYMNHL0020
, 4328-07, 95140, LYMNHL0020, NCT00185731, NCT00185731
24.
Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
INST 1003C
, NCT00250718
25.
Phase II Study of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Non-Hodgkin's or Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Under 70
Sponsor:
NCI
Protocol IDs:
UMN-2005LS048
, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Select All on Page
1
Help with Results
